- Conditions
- Neuroblastoma
- Interventions
- DFMO
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–22
of 22
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Neuroblastoma
- Interventions
- Eflornithine
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 31 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2033
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
- Conditions
- Pontine Glioma
- Interventions
- Vismodegib
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 3 Years to 18 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Grand Rapids, Michigan
- Conditions
- Relapsed Neuroblastoma
- Interventions
- Cerebral Spinal (CS) radiation, Focal radiotherapy (SRS)
- Radiation
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Neuroblastoma
- Interventions
- TPI 287, Temozolomide, Irinotecan
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • San Diego, California • Hartford, Connecticut + 5 more
- Conditions
- Neuroblastoma
- Interventions
- DFMO, Etoposide
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Not listed
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 7
- States / cities
- Orange, California • Hartford, Connecticut • Orlando, Florida + 4 more
- Conditions
- Neuroblastoma, Medulloblastoma, Glioma, Ependymoma, Choroid Plexus Neoplasms, Craniopharyngioma, Dysembryoplastic Neuroepithelial Tumor, Meningioma, Primitive Neuroectodermal Tumors (PNETs), Germ Cell Tumors, Rhabdomyosarcoma, Non-rhabdomyosarcoma, Ewings Sarcoma, Osteosarcoma, Wilms Tumor, Renal Cell Carcinoma, Malignant Rhabdoid Tumor, Clear Cell Sarcoma, Liver Tumors
- Interventions
- Guided Therapy
- Device
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 13 Months to 21 Years
- Enrollment
- 186 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more
- Conditions
- Pediatric Cancer, Survivorship
- Interventions
- No intervention- registry only
- Other
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2032
- U.S. locations
- 18
- States / cities
- Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 15 more
- Conditions
- Refractory Neuroblastoma, Relapsed Neuroblastoma
- Interventions
- Not listed
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- Neuroblastoma, Medulloblastoma, Brain Tumors, Rare Tumors
- Interventions
- Guided Therapy- Pediatric Gene Analysis Platform
- Device
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 13 Months and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2024
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • San Diego, California • Hartford, Connecticut + 10 more
- Conditions
- Neuroblastoma
- Interventions
- Guided Therapy
- Device
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 1 Year and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 7
- States / cities
- Hartford, Connecticut • Orlando, Florida • Bethesda, Maryland + 4 more
- Conditions
- Neuroblastoma, Medulloblastoma, Relapse
- Interventions
- TPI 287
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 6
- States / cities
- San Diego, California • Orlando, Florida • St Louis, Missouri + 3 more
- Conditions
- Neuroblastoma
- Interventions
- Ceritinib, dasatinib, sorafenib, vorinostat, DFMO
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 22 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2035
- U.S. locations
- 24
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 21 more
- Conditions
- Neuroblastoma, Medulloblastoma, Typical Teratoid Rhabdoid Tumor, Embryonal Tumor With Abundant Neuropil and True Rosettes, Ependymoblastoma, Medulloepithelioma
- Interventions
- eflornithine HCl
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 0 Years to 30 Years
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Neuroblastoma, Medulloblastoma
- Interventions
- Nifurtimox, Cyclophosphamide, Topotecan
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2022
- U.S. locations
- 15
- States / cities
- San Diego, California • Hartford, Connecticut • Orlando, Florida + 12 more
- Conditions
- Neuroblastoma
- Interventions
- Difluoromethylornithine (DFMO)
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 441 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2033
- U.S. locations
- 41
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 38 more
- Conditions
- Neuroblastoma Recurrent
- Interventions
- DFMO, Bortezomib
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 6
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Orlando, Florida + 3 more
- Conditions
- Neuroblastoma
- Interventions
- Tolcapone, Oxaliplatin
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 0 Years to 21 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • San Diego, California • Hartford, Connecticut + 6 more
- Conditions
- Medulloblastoma
- Interventions
- Difluoromethylornithine
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 25
- States / cities
- Little Rock, Arkansas • Oakland, California • Sacramento, California + 22 more
- Conditions
- Neuroblastoma
- Interventions
- Naxitamab
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2036
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 18 more
- Conditions
- Neuroblastoma, Medulloblastoma
- Interventions
- TPI 287
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 12 Months to 30 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 8
- States / cities
- San Diego, California • Hartford, Connecticut • Orlando, Florida + 5 more
- Conditions
- Neuroblastoma
- Interventions
- Tipifarnib, Naxitamab
- Drug
- Lead sponsor
- Giselle Sholler
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 98 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 12
- States / cities
- Little Rock, Arkansas • Hartford, Connecticut • Miami, Florida + 9 more